INTRODUCTION
The bipolar disorder market is experiencing a renewed expansion in product
life-cycle management. Presently, mood stabilizers are the basis of treatment,
although the antipsychotics led by Zyprexa, are evolving as a new therapeutic
strategy. Companies will have to differentiate their products in the
increasingly crowded market if they wish to protect their market share.
SCOPE OF THE REPORT
- Analysis is based on a survey of 164 treating physicians in the seven
major markets as well as in-depth interviews with Bipolar key opinion
leaders
- Detailed treatment trees showing the prevalence, diagnosis and treatment
rates of bipolar across the seven major markets
- Assessment of the use of mono- and combination-therapy in specific bipolar
affective episodes
- Identification of therapeutic and diagnostic unmet needs, highlights areas
where stakeholder investment is vital to drive patient identification
REPORT HIGHLIGHTS
Datamonitor primary research has identified variances in class and brand
prescribing preferences among physicians, according to BD type and geography;
although prescribing trends generally follow recognized national and
international guidelines. However, there is concern over the use of tricyclic
antidepressants in bipolar depression. Only 48% of the BD population are
accurately diagnosed. Datamonitor has highlighted a number of serious diagnostic
issues, which infers that many of the patients currently diagnosed may receive
incorrect BD categorization. Lilly's Zyprexa is currently leading the bipolar
market in terms of revenue and life cycle management, with recent approval for
maintenance therapy and reformulation in a combination pill with Prozac as
Symbyax. Other atypical antipsychotics appear to be following suit, and could
threaten anticonvulsant dominance of mood stabilization.
KEY REASONS TO BUY THIS REPORT
- Understand differential treatment unmet needs in key patient populations
identified by sex, co-morbidities and bipolar disorder type
- Gain expert insight into current diagnostic unmet needs and key growth
areas in the public and healthcare sectors
- Target physicians more effectively, through an understanding of
prescribing behavior
| 
View Cart
